BackClarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings Long Term Debt

Clarus Therapeutics Holdings's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
100.00% YoYΔ $-108.93M vs prior year quarter

Peer average

Loading

Clarus Therapeutics Holdings Long Term Debt History

Loading

Clarus Therapeutics Holdings vs. peers: Long Term Debt Comparison

Loading

Clarus Therapeutics Holdings Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Clarus Therapeutics Holdings (CRXT) FAQ

As of the most recent data (June 2022), CRXT shows a long-term debt of $0. That compares with $110M in the prior-year period — down 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CRXT's long-term debt is now $0 (was $110M) — a 100.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Clarus Therapeutics Holdings is outperforming or lagging.

Tracking CRXT's long-term debt over time shows whether Clarus Therapeutics Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $110M in the prior-year period — down 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Clarus Therapeutics Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.